DNA aneuploidy‐specific therapy for head and neck squamous cell carcinoma

E-ISSN： 1097-0347|37|6|884-888

ISSN： 1043-3074

Source： HEAD & NECK: JOURNAL FOR THE SCIENCES & SPECIALTIES OF THE HEAD AND NECK, Vol.37, Iss.6, 2015-06, pp. : 884-888

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

BackgroundPatients with head and neck squamous cell carcinoma (HNSCC) have an unfavorable prognosis, with a 5‐year survival rate of approximately 40%. Genetic analyses have revealed that the majority of HNSCCs carry complex, aneuploid karyotypes, showing numerical and structural chromosomal imbalances. New compounds are being developed that target chromosomal instability in general, specifically affecting cells with aneuploid karyotypes.MethodsTwo such compounds, 5‐aminoimidazole‐4‐carboxamide riboside (AICAR) and 17‐allylamino‐17‐demethoxygeldanamycin (17‐AAG), were tested using a panel of stable diploid and unstable aneuploid HNSCC cell lines, and short‐term cultures of normal keratinocytes as control.ResultsA significant growth inhibitory effect by both compounds was observed in the aneuploid compared to diploid HNSCC cell lines and to the normal keratinocytes. This effect was independent from the TP53 mutation status. Combination treatment with AICAR and 17‐AAG demonstrated the strongest inhibition.ConclusionAneuploidy‐targeted therapy may be a viable addition to the treatment options for HNSCC.<copy;2013> © 2014 Wiley Periodicals, Inc. Head Neck 37: 884–888, 2015